PubMed Health⌕ Search

Biomedical subjects

W G Straffon

Publications and source records attributed to W G Straffon.

14 recordsLinked to original sources
PubMed1985

Testicular vein ligation and fertility in men with varicoceles.

Pregnancy rates in 651 subfertile couples in which the man had a varicocele were analysed by life table methods and were not found to be significantly different before and after testicular vein ligation performed in 283 patients. Estimated proportions of couples conceiving were roughly 30% by one year and 45% by two years in both groups. The operation was also not associated with improvement in results of semen analysis. These findings suggest that testicular vein ligation for varicoceles does not improve fertility.

Female↗
PubMed1984

A controlled trial of the use of erythromycin for men with asthenospermia.

A double-blind crossover controlled trial of Erythromycin was conducted in 78 men with asthenospermia (mean pretreatment sperm concentration greater than or equal to 20 X 10(6)/ml and motility less than 60%). Sperm motility increased above the pretreatment mean after the first one month course of treatment for both Erythromycin (7.9 +/- 2.6% P less than 0.01; mean +/- SEM) and the placebo group (7.5 +/- 2.2% P less than 0.01) and also after the second one month course of treatment, given one month after the first, for both Erythromycin (11.8 +/- 2.7% P less than 0.001) and placebo (11.4 +/- 2.8% P less than 0.001). There was no significant difference between the changes in sperm motility with Erythromycin and placebo. Twelve pregnancies occurred during the four month trial time--eight with Erythromycin and four with placebo (chi 2 = 2.51 P = NS). It is concluded that in infertile men, sperm motility tends to increase spontaneously with time. Erythromycin treatment has no significant effect on semen quality and a larger trial will be required to determine if Erythromycin increases fertility.

Clinical Trials as Topic↗
PubMed1982

Retarding the uptake of "mock venom" in humans: comparison of three first-aid treatments.

We compared, for the first time in human subjects, first-aid measures to treat bites from Australian snakes using a "mock venom" (congruent to 0.2 mL of Na 131I at 7.4 kBq or 11.1 kBq (0.2 muCi/kg or 0.3 muCi/kg)) as a subcutaneous injection in the lateral aspect of the leg. After application of either a full-length lower-limb airsplint (inflated to 7.3 +/- 0.7 kPa (55 +/- 5 mmHg) pressure) or the currently recommended treatment (elastic bandages at 7.3 +/- 0.7 kPa (55 +/- 5 mmHg) pressure and supporting splint) the rate of appearance of the Na 131I in the peripheral blood was approximately the same as the ratio for the untreated controls. However, application of a large firm pad over the injection site and its immediate surrounds, retained by a non-elastic bandage (at least 9.3 kPa (70 mmHg) pressure over the injection site), completely prevented "mock venom" uptake until the pad was removed. Further investigations are proceeding.

Adult↗
PubMed1975

The assessment of results following endocrine therapy for prostatic cancer.

Generally, recent reports on the side effects of estrogen therapy for prostatic cancer have concerned mortality statistics, relatively little attention having been paid to the quality of life of individual patients. We herein propose an assessment of treatment regimens based on the concept of the time during which a patient remains free of tumor progression or serious side effects. A particular regimen has been examined in relation to the hormonal effects of endocrine ablation, and to the dosage and type of estrogen therapy used in 59 men with prostatic cancer. Although no significant difference among treatment methods has emerged in this small group (except for the more frequent occurrence of fluid retention with the stilbestrol dosage, 30 versus 15 mg. per day) and no correlation between the degree of testosterone suppression and length of remission has emerged so far, this method of assessment proved useful and should be applicable widely. It was confirmed that gonadotropin levels remained in the normal range in patients whose testosterone levels were suppressed with chlorotrianisene.

Chlorotrianisene↗